Back
Back
SPI-62-CL-2001
Official Title
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Study Details
The purpose of this study is to find out about the safety and efficacy of an experimental drug for the possible treatment of Cushing's syndrome.
Principal Investigator
Dr. Julie Silverstein
IRB Number
202203156
Eligibility
1. Participants must have documented diagnosis of ACTH-dependent Cushings's syndrome
2. Participants must be age 18 or older
Volunteer Information
For more information about this study, contact Volunteer for Health at:
- 314.362.1000
- rprstaff@wustl.edu